진단 플랫폼 간 종양 돌연변이 부하(TMB) 정량화 일치: Friends of Cancer Research TMB 조화 프로젝트 2단계

Vega 등(Fri,)이 이 문제를 연구하였습니다.

www.synapsesocial.com/papers/69d96f421ad561c673684296 — DOI: https://doi.org/10.1016/j.annonc.2021.09.016

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project· 2020 · 502 citations
2. Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer· 2018 · 12 citations
3. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer· 2016 · 38 citations
4. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence· 2020 · 1,180 citations
5. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project· 2016 · 1,242 citations